William Blair initiates Cytokinetics stock coverage with outperform rating

Investing.com reports that William Blair has started covering Cytokinetics Inc (NASDAQ:CYTK) with an Outperform rating and a price target of $101 per share. Based on discounted cash flow valuation, this represents an 58% upside from the current stock price of $63.92, which is close to InvestingPro's Fair Value estimate of $62.94.

The bullish outlook aligns with Wall Street consensus, with analysts holding a Strong Buy rating and price targets ranging from $85 to $146. William Blair is confident in the commercial launch of MYQORZO, the company's first approved product, through 2027. The specialty cardiology company generated $67.67 million in revenue over the last year, but analysts don't anticipate profitability this year.

Cytokinetics maintains a strong current ratio of 6.66, indicating sufficient liquidity to fund its expansion. The firm anticipates approval for nHCM around mid-2027, which would add approximately 100,000 addressable patients to the market opportunity. By 2032, Cytokinetics projects sales of around $3.74 billion. Key risks include the MYQORZO commercial launch, regulatory matters, and clinical execution.

Recent developments have put Cytokinetics in the spotlight, with UBS lowering its price target to $104 while maintaining a Buy rating, Cantor Fitzgerald reiterating an Overweight rating, and Truist Securities setting a $112 price target. Cytokinetics has also filed a declaratory judgment action against Bristol-Myers Squibb and MyoKardia, disputing a U.S. patent's validity. H.C. Wainwright recently renewed its Buy rating with a $140 price target following this legal move.